By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
London TelegraphLondon TelegraphLondon Telegraph
  • Home
  • World
  • Europe
  • USA
  • Middle East
  • Asia
  • General
  • Business
  • Entertainment
  • Technology
  • Health
  • Sports
  • Newsroom
  • Opinions
Reading: New cancer vaccine delivers stunning result against one of the deadliest skin cancers
Share
Notification Show More
Font ResizerAa
London TelegraphLondon Telegraph
Font ResizerAa
  • World
  • Travel
  • Science
  • Technology
  • Home
    • Home 1
    • Home 2
    • Home 3
    • Home 4
    • Home 5
  • Categories
    • Technology
    • Travel
    • World
    • Science
    • Health
  • Bookmarks
  • More Foxiz
    • Sitemap
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

New cancer vaccine delivers stunning result against one of the deadliest skin cancers

Last updated: June 3, 2026 9:38 pm
RNN
6 months ago
Share
New cancer vaccine delivers stunning result against one of the deadliest skin cancers
SHARE

A new injectable therapy is showing positive results in throughout a five-year period.

The personalized , called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna.

The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.

After about a five-year follow-up, the combo drug was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone.

The researchers analyzed data from 157 patients with high-risk whose cancer had been removed via surgery. The participants were split into two groups — one received the combo therapy and the other only received pembrolizumab, according to a press release.

The findings revealed that the combination group saw benefits that were “sustained and durable over time.”

Intismeran autogene is designed using mutations identified in a patients own tumor, with the intention of teaching the what the cancer looks like so that it can recognize and attack it.

According to the researchers, intismeran is “well-tolerated” with a “manageable” safety profile. 

The most commonly cited side effects of the personalized mRNA vaccine plus KEYTRUDA were fatigue, injection-site pain, chills, fever and headache. The researchers reported no new long-term safety concerns and no severe vaccine-related adverse events.

The combination therapy is currently being evaluated in a phase 3 study — the final confirmation stage.

In a Merck press release from January, Kyle Holen, MD, Modernas senior vice president and head of development, oncology and therapeutics, noted that this data highlights the “potential of a … in patients with resected high-risk melanoma.”

“We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNAs potential in cancer care,” he said.  

Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, also commented that for many patients with stage 3 or 4 melanoma, there is a “significant risk of recurrence .”

“As such, demonstrating the longer-term potential of intismeran autogene and KEYTRUDA to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone,” she said.

The company cited encouraging five-year follow-up data and pointed to upcoming late-stage INTerpath trial results with Moderna in several .

Top 5 Questions to Ask When Choosing a Uniform Rental Company
Forecasters warn of tornadoes in US in coming days
‘God Bless the USA’ star revives patriotic spirits brand benefiting veterans for America’s 250th birthday
Smithsonians dark take on America exposed: Washington dubbed town destroyer, Revolutionary War dangerous’
Peptide Associates Launches Next-Generation GLP-3/Triple G Injections with Streamlined Access Approach
TAGGED:EventsHealthPress ReleaseResearch
Share This Article
Facebook Email Print
Previous Article Why Myles Garrett Waived His No-Trade Clause To Finalize Move To The Rams Why Myles Garrett Waived His No-Trade Clause To Finalize Move To The Rams
Next Article Booker set to face Navy vet after former local NJ official lost in 2024 Senate race Booker set to face Navy vet after former local NJ official lost in 2024 Senate race
about us

Runway News Network (RNN) is a UK-based digital media group operating multiple independent news platforms across the United Kingdom. We provide structured journalism, press syndication and AI-optimised news distribution for organisations seeking national and regional visibility.

Find Us on Socials

London TelegraphLondon Telegraph
© Runway News Network. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?